Abstract
This chapter considers general aspects and clinical features of retinoblastoma, an intraocular malignancy of primitive neuroendocrine origin that primarily affects young children. In the United States, the age-adjusted incidence of retinoblastoma is approximately 11.8 per million children aged 0–4 years, which represents 6.1 % of all childhood cancers under age 5 years. Depending on the classification of the tumor, globe-sparing treatment may be advised and should be performed by a clinician with experience in the treatment of retinoblastoma. A number of treatment options are available including local or systemic chemotherapy, chemoreduction, photocoagulation, thermotherapy, cryotherapy, brachytherapy, and enucleation. Treatment selection is complex and should be personalized to every case through a multidisciplinary approach. Genetic counseling is integral to the management of retinoblastoma patients.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Singh AD, Damato BE, Peer J, Murphree AL, Perry JD. Clinical ophthalmic oncology. 2nd ed. Philadelphia: Saunders; 2007.
Bunin G, Orjuela M. Geographic and environmental factors. In: Singh AD, Damato BE, Peer J, editors. Clinical ophthalmic oncology. Philadelphia: Saunders-Elsevier; 2007. p. 410–6.
Broaddus E, Topham A, Singh AD. Incidence of retinoblastoma in the USA: 1975–2004. Br J Ophthalmol. 2009;93(1):21–3.
Parkin DM, Stiller CA, Draper GJ, Bieber CA. The international incidence of childhood cancer. Int J Cancer. 1988;42(4):511–20.
Albert DM. Historic review of retinoblastoma. Ophthalmology. 1987;94(6):654–62.
Knudson Jr AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68(4):820–3.
Zhang J, Schweers B, Dyer MA. The first knockout mouse model of retinoblastoma. Cell Cycle. 2004;3(7):952–9.
Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science. 1988;241(4863):353–7.
Lee EY, To H, Shew JY, Bookstein R, Scully P, Lee WH. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science. 1988;241(4862):218–21.
Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR. The E2F transcription factor is a cellular target for the RB protein. Cell. 1991;65(6):1053–61.
Bagchi S, Weinmann R, Raychaudhuri P. The retinoblastoma protein copurifies with E2F-I, an E1A-regulated inhibitor of the transcription factor E2F. Cell. 1991;65(6):1063–72.
Abramson DH, Schefler AC. Update on retinoblastoma. Retina. 2004;24(6):828–48.
Kivela T. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol. 1999;17(6):1829–37.
Singh AD, Shields CL, Shields JA. New insights into trilateral retinoblastoma. Cancer. 1999;86(1):3–5.
Abramson DH, Frank CM, Susman M, Whalen MP, Dunkel IJ, Boyd III NW. Presenting signs of retinoblastoma. J Pediatr. 1998;132(3 Pt 1):505–8.
Gallie BL, Ellsworth RM, Abramson DH, Phillips RA. Retinoma: spontaneous regression of retinoblastoma or benign manifestation of the mutation? Br J Cancer. 1982;45(4):513–21.
Singh AD, Santos CM, Shields CL, Shields JA, Eagle Jr RC. Observations on 17 patients with retinocytoma. Arch Ophthalmol. 2000;118(2):199–205.
Novetsky DE, Abramson DH, Kim JW, Dunkel IJ. Published international classification of retinoblastoma (ICRB) definitions contain inconsistencies—an analysis of impact. Ophthalmic Genet. 2009;30(1):40–4.
Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am. 2005;18(1):41–53. viii.
Sant M, Capocaccia R, Badioni V. Survival for retinoblastoma in Europe. Eur J Cancer. 2001;37(6):730–5.
Kaneko A, Suzuki S. Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol. 2003;33(12):601–7.
Abramson DH, Marr BP, Dunkel IJ, Brodie S, Zabor EC, Driscoll SJ, et al. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. Br J Ophthalmol. 2012;96(4):499–502.
Marr B, Gobin PY, Dunkel IJ, Brodie SE, Abramson DH. Spontaneously resolving periocular erythema and ciliary madarosis following intra-arterial chemotherapy for retinoblastoma. Middle East Afr J Ophthalmol. 2010;17(3):207–9.
Mendelsohn ME, Abramson DH, Madden T, Tong W, Tran HT, Dunkel IJ. Intraocular concentrations of chemotherapeutic agents after systemic or local administration. Arch Ophthalmol. 1998;116(9):1209–12.
Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology. 1999;106(10):1947–50.
Schmack I, Hubbard GB, Kang SJ, Aaberg Jr TM, Grossniklaus HE. Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma. Am J Ophthalmol. 2006;142(2):310–5.
Abramson DH, Ellsworth RM, Rozakis GW. Cryotherapy for retinoblastoma. Arch Ophthalmol. 1982;100(8):1253–6.
Abramson DH, Schefler AC. Transpupillary thermotherapy as initial treatment for small intraocular retinoblastoma: technique and predictors of success. Ophthalmology. 2004;111(5):984–91.
Shields CL, Shields JA, De Potter P, Hernandez C, Brady LW. Plaque radiotherapy for retinoblastoma. Int Ophthalmol Clin. 1993;33(3):107–18.
Abramson DH. Super selective ophthalmic artery delivery of chemotherapy for intraocular retinoblastoma: ‘chemosurgery’ the first Stallard lecture. Br J Ophthalmol. 2010;94:396–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Medina, C.A., Kumar, P., Singh, A.D. (2016). Retinoblastoma. In: Traboulsi, E., Utz, V. (eds) Practical Management of Pediatric Ocular Disorders and Strabismus. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2745-6_37
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2745-6_37
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-2744-9
Online ISBN: 978-1-4939-2745-6
eBook Packages: MedicineMedicine (R0)